The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) recently released the 2012 status report on pharmaceutical R&D to address diseases that disproportionately affect people in low- and middle-income countries.
"Representing a 40 percent increase over 2011, the 132 R&D projects in the 2012 update focus on the following diseases prioritized by the World Health Organization's Special Programme for Research and Training in Tropical Diseases (TDR): tuberculosis, malaria, human African trypanosomiasis (sleeping sickness), leishmaniasis, dengue, onchocerciasis (River blindness), American trypanosomiasis (Chagas disease), schistosomiasis, leprosy and lymphatic filariasis.
Collaboration continues to be an integral aspect of the industry’s approach to these diseases. Of the 132 R&D projects listed in this status report, 112 (85%) are product development partnerships (PDPs) while the remaining 20 (15%) projects are company-only undertakings.
As part of the 2012 London Declaration on Neglected Diseases, the research-based pharmaceutical industry pledged continued R&D and donations of 14 billion treatments by 2020 to control or eliminate nine neglected diseases."
- IFPMA Press Release